Acadia Healthcare Company, Inc. (ACHC) Stock Analysis and Metrics

Acadia Healthcare Company

NASDAQ: ACHC

$34.50 ▲ +0.89 (+2.65%)

At close: Jul 17, 2026 · 3:59 PM UTC

Financial Ratios

Market Cap28.38 Mn

P/E-0.03

P/S0.01

Div. Yield0.00

ROIC (Qtr)-0.01

Total Debt (Qtr)2.53 Bn

Revenue Growth (1y) (Qtr)7.57

Add ratio to table…

About

Acadia Healthcare Company, Inc. is a leading provider of behavioral healthcare services in the United States, operating a network of facilities that deliver acute inpatient psychiatric care, specialty treatment for substance use and co-occurring disorders, comprehensive treatment centers focused on medication-assisted treatment, and residential treatment centers for individuals with moderate to high acuity behavioral health needs. The company serves patients requiring stabilization and ongoing support for mental illness, addiction, and related conditions through a continuum of care designed to address complex and high-acuity populations.

Acadia Healthcare Company, Inc. generates revenue by providing behavioral healthcare services across its facility network, receiving payments from state Medicaid programs, commercial insurers, the federal Medicare program, and individual patients. The company’s revenue is derived from acute inpatient psychiatric facilities, specialty treatment facilities, comprehensive treatment centers, and residential treatment centers, with service delivery supported by clinical staff including psychiatrists, therapists, nurses, and counselors who deliver evaluation, detoxification, medication-assisted treatment, therapy, and recovery planning.

The company operates through the following segments: Acute inpatient psychiatric facilities, Specialty treatment facilities, Comprehensive treatment centers, and Residential treatment centers.

• Acute inpatient psychiatric facilities provide 24-hour observation, daily intervention, and monitoring by psychiatrists to stabilize patients who are a threat to themselves or others, offering evaluation and crisis stabilization for severe psychiatric diagnoses through structured medical and behavioral therapies with typical lengths of stay ranging from three to twelve days.

• Specialty treatment facilities primarily consist of residential recovery facilities that provide a continuum of care for adults with addictive disorders and co-occurring mental disorders, offering detoxification, inpatient, partial hospitalization, and outpatient treatment in a supportive environment with individualized programs using modalities such as twelve-step philosophy and cognitive behavioral therapies.

• Comprehensive treatment centers specialize in medication-assisted treatment for opioid use disorders in an outpatient setting, combining behavioral therapy with medication to normalize brain chemistry and block euphoric effects of opioids, while providing services such as treatment planning, medication management, individual and group therapy, peer support, vocational training, and social support.

• Residential treatment centers treat patients with behavioral disorders in a non-hospital setting, balancing therapy with social, academic, and other activities through medically driven interventions and individualized treatment regimens for moderate to high acuity patients, including adolescents with histories of trauma, substance abuse, and psychiatric disorders, with lengths of stay ranging from three months to several years.

Acadia Healthcare Company, Inc. is a leading publicly traded pure-play provider of behavioral healthcare services in the U. S., positioned as a dominant platform in a highly fragmented industry, with competitive advantages derived from its national footprint, scale, diversified revenue and payor bases, and experienced management team with deep expertise in healthcare operations and clinical care.

The company serves patients referred by healthcare practitioners, public programs, other treatment facilities, managed care organizations, unions, emergency departments, judicial officials, social workers, police departments, and word of mouth from previously treated patients and their families, with a payor mix consisting of 57.7% Medicaid, 24.6% commercial payors, 14.3% Medicare, and 3.4% other payors for the year ended December 31, 2025.

Investment Thesis

▲ Bull case

Acadia Healthcare's operational restructure and leadership changes are driving underappreciated execution improvements that could unlock significant value from its recent facility investments. The reorganization of the acute service line into smaller geographic divisions with clearer oversight and the creation of a dedicated operating group for joint ventures and new facilities reflect a deliberate effort to eliminate complexity and improve accountability. This structural shift, combined with talent reviews and the hiring of experienced leaders for underperforming de novos, is already yielding results as evidenced by Q1 revenue and adjusted EBITDA from facilities opened since 2023 exceeding expectations. The company's focus on standardizing new hospital launches and applying learnings from past openings reduces execution risk for its 2026 pipeline, which includes the upcoming Orlando Health and Methodist Jenny Edmondson joint ventures. These actions suggest that the $200 million adjusted EBITDA growth target relative to 2025 for the post-2023 facility cohort is conservative, as early traction indicates faster ramp-up than modeled, potentially accelerating free cash flow generation and supporting the revised full-year EBITDA guidance range of $580 million to $615 million.
The company's disciplined approach to cost management and workforce efficiency is creating a sustainable margin expansion tailwind that is not fully reflected in current guidance. Acadia's reduction in corporate headcount, elimination of redundant management layers, and focus on aligning staffing with patient needs through better real-time visibility tools are directly addressing historical inefficiencies such as premium labor. These initiatives contributed to the $7.2 million EBITDA beat in Q1 and are expected to provide benefits throughout the year, as noted by Todd Young regarding cost programs implemented at the end of Q1. With staff retention improving for the eighth consecutive quarter and labor management training reducing inefficiencies without sacrificing quality, the company is building a more stable operational foundation. This efficiency drive, coupled with the reversal of a $3.2 million employee benefit cost headwind in the back half of 2026, positions Acadia to deliver EBITDA growth beyond the guided range, particularly as supplemental payment programs under regulatory review could add at least $22 million in incremental EBITDA if approved— a figure management suggests may be conservative based on evolving insights into Ford's plan.
Acadia's strategic focus on strengthening referral networks and leveraging outcome data presents a powerful but underdiscussed catalyst for volume growth and payer partnerships. The emphasis on communicating clinical outcomes to referral sources—through enhanced tracking, website disclosures, and treatment placement specialists—addresses a critical unspoken need in behavioral health where payers and providers increasingly prioritize measurable results. The strong performance of specialty facilities attracting national patients and the active effort to refill Pennsylvania beds through outreach to surrounding states demonstrate effective network diversification. Combined with a 20% increase in acute inquiries and robust RTC census, this referral-centric strategy is not merely defensive but offensive, positioning Acadia to capture share in a growing market. As the company scales outcome validation, it could command better contract terms and reduce denial rates, turning a current headwind into a long-term advantage that supports both volume expansion and margin improvement beyond what is currently priced in.

Acadia Healthcare's operational restructure and leadership changes are driving underappreciated execution improvements that could unlock significant value from its recent facility investments. The reorganization of the acute service line into smaller geographic divisions with clearer oversight and the creation of a dedicated operating group for joint ventures and new facilities reflect a deliberate effort to eliminate complexity and improve accountability. This structural shift, combined with talent reviews and the hiring of experienced leaders for underperforming de novos, is already yielding results as evidenced by Q1 revenue and adjusted EBITDA from facilities opened since 2023 exceeding expectations. The company's focus on standardizing new hospital launches and applying learnings from past openings reduces execution risk for its 2026 pipeline, which includes the upcoming Orlando Health and Methodist Jenny Edmondson joint ventures. These actions suggest that the $200 million adjusted EBITDA growth target relative to 2025 for the post-2023 facility cohort is conservative, as early traction indicates faster ramp-up than modeled, potentially accelerating free cash flow generation and supporting the revised full-year EBITDA guidance range of $580 million to $615 million.
The company's disciplined approach to cost management and workforce efficiency is creating a sustainable margin expansion tailwind that is not fully reflected in current guidance. Acadia's reduction in corporate headcount, elimination of redundant management layers, and focus on aligning staffing with patient needs through better real-time visibility tools are directly addressing historical inefficiencies such as premium labor. These initiatives contributed to the $7.2 million EBITDA beat in Q1 and are expected to provide benefits throughout the year, as noted by Todd Young regarding cost programs implemented at the end of Q1. With staff retention improving for the eighth consecutive quarter and labor management training reducing inefficiencies without sacrificing quality, the company is building a more stable operational foundation. This efficiency drive, coupled with the reversal of a $3.2 million employee benefit cost headwind in the back half of 2026, positions Acadia to deliver EBITDA growth beyond the guided range, particularly as supplemental payment programs under regulatory review could add at least $22 million in incremental EBITDA if approved— a figure management suggests may be conservative based on evolving insights into Ford's plan.
Acadia's strategic focus on strengthening referral networks and leveraging outcome data presents a powerful but underdiscussed catalyst for volume growth and payer partnerships. The emphasis on communicating clinical outcomes to referral sources—through enhanced tracking, website disclosures, and treatment placement specialists—addresses a critical unspoken need in behavioral health where payers and providers increasingly prioritize measurable results. The strong performance of specialty facilities attracting national patients and the active effort to refill Pennsylvania beds through outreach to surrounding states demonstrate effective network diversification. Combined with a 20% increase in acute inquiries and robust RTC census, this referral-centric strategy is not merely defensive but offensive, positioning Acadia to capture share in a growing market. As the company scales outcome validation, it could command better contract terms and reduce denial rates, turning a current headwind into a long-term advantage that supports both volume expansion and margin improvement beyond what is currently priced in.

▼ Bear case

Acadia Healthcare's reliance on volatile supplemental payment programs introduces significant and understated revenue volatility that could undermine its full-year guidance, despite management's optimism about approval prospects. While Todd Young noted that certain programs under regulatory review could add at least $22 million in incremental EBITDA if approved, he also acknowledged that the $22 million figure may be conservative based on Ford's plan insights—yet crucially, no unapproved programs are included in guidance. This creates a binary risk: if these programs fail to materialize, the company loses a meaningful tailwind, but if they do arrive, the benefit may already be partially anticipated by the market. More concerning is the historical precedent of volatility, as evidenced by the substantial out-of-period supplemental payments from Tennessee in Q2 2025 that distorted year-over-year comparisons and forced Acadia to issue atypical Q2 2026 guidance for clarity. The company's net leverage ratio is expected to rise to 4.4x–4.5x adjusted EBITDA by end of Q2 due to this very volatility, exceeding the 3.9x–4.2x range guided for year-end, highlighting how supplemental swings can disrupt financial stability and increase financing costs even if temporary.
The company's aggressive bed expansion strategy, while framed as a response to strong demand, carries substantial execution and financial risks that are being downplayed in favor of growth narratives. Acadia plans to add 400–600 beds in 2026 while simultaneously reducing capital investment by over $300 million compared to 2025, suggesting a reliance on near-complete facilities and existing asset expansions rather than greenfield builds. However, the $12 million in Q1 start-up facility losses—$2 million better than forecast but still material—reveal that even recently opened facilities (post-2023) are not yet contributing meaningfully to profitability, with losses only improving due to operating efficiency fixes rather than organic ramp-up. The need for tailored action plans for each underperforming de novo, including questions around CON approval and licensure, implies persistent barriers to occupancy that management's referral focus may not quickly overcome. With 251 beds closed in Q1 (primarily leased facilities in Pennsylvania) offsetting the 82 beds added, net capacity growth remains negative in the short term, raising doubts about whether the 2026 bed addition target will translate to timely revenue contribution or merely replace churn.
Payer-related headwinds in revenue cycle management are more structural and persistent than management's characterization of them as temporary stabilizations, posing a continuing threat to cash flow and profitability. Todd Young admitted that bad debts and denials "continue to get a little bit worse in Q1 than what we had previously expected," despite earlier assumptions of stabilization in Q4, and that responses to collection efforts are "running a little hotter than expected." The decision to bring back Larry Hard on a temporary consulting basis—after his prior success during Debra Osteen's last tenure—underscores the depth of the issue, suggesting that internal process fixes and tools like early-stage AI in revenue cycle management are insufficient to resolve systemic problems. The reflection of these challenges in full-year expectations for higher-than-expected bad debts and denials offsetting specialty business improvements indicates that this is not a transient issue but a worsening trend tied to broader payer scrutiny of behavioral health claims, potentially driven by increasing audit activity or shifting coverage policies that could persist beyond 2026, eroding margins and increasing working capital strain.

Acadia Healthcare's reliance on volatile supplemental payment programs introduces significant and understated revenue volatility that could undermine its full-year guidance, despite management's optimism about approval prospects. While Todd Young noted that certain programs under regulatory review could add at least $22 million in incremental EBITDA if approved, he also acknowledged that the $22 million figure may be conservative based on Ford's plan insights—yet crucially, no unapproved programs are included in guidance. This creates a binary risk: if these programs fail to materialize, the company loses a meaningful tailwind, but if they do arrive, the benefit may already be partially anticipated by the market. More concerning is the historical precedent of volatility, as evidenced by the substantial out-of-period supplemental payments from Tennessee in Q2 2025 that distorted year-over-year comparisons and forced Acadia to issue atypical Q2 2026 guidance for clarity. The company's net leverage ratio is expected to rise to 4.4x–4.5x adjusted EBITDA by end of Q2 due to this very volatility, exceeding the 3.9x–4.2x range guided for year-end, highlighting how supplemental swings can disrupt financial stability and increase financing costs even if temporary.
The company's aggressive bed expansion strategy, while framed as a response to strong demand, carries substantial execution and financial risks that are being downplayed in favor of growth narratives. Acadia plans to add 400–600 beds in 2026 while simultaneously reducing capital investment by over $300 million compared to 2025, suggesting a reliance on near-complete facilities and existing asset expansions rather than greenfield builds. However, the $12 million in Q1 start-up facility losses—$2 million better than forecast but still material—reveal that even recently opened facilities (post-2023) are not yet contributing meaningfully to profitability, with losses only improving due to operating efficiency fixes rather than organic ramp-up. The need for tailored action plans for each underperforming de novo, including questions around CON approval and licensure, implies persistent barriers to occupancy that management's referral focus may not quickly overcome. With 251 beds closed in Q1 (primarily leased facilities in Pennsylvania) offsetting the 82 beds added, net capacity growth remains negative in the short term, raising doubts about whether the 2026 bed addition target will translate to timely revenue contribution or merely replace churn.
Payer-related headwinds in revenue cycle management are more structural and persistent than management's characterization of them as temporary stabilizations, posing a continuing threat to cash flow and profitability. Todd Young admitted that bad debts and denials "continue to get a little bit worse in Q1 than what we had previously expected," despite earlier assumptions of stabilization in Q4, and that responses to collection efforts are "running a little hotter than expected." The decision to bring back Larry Hard on a temporary consulting basis—after his prior success during Debra Osteen's last tenure—underscores the depth of the issue, suggesting that internal process fixes and tools like early-stage AI in revenue cycle management are insufficient to resolve systemic problems. The reflection of these challenges in full-year expectations for higher-than-expected bad debts and denials offsetting specialty business improvements indicates that this is not a transient issue but a worsening trend tied to broader payer scrutiny of behavioral health claims, potentially driven by increasing audit activity or shifting coverage policies that could persist beyond 2026, eroding margins and increasing working capital strain.

Segments Breakdown of Revenue (2025)

Peer Comparison

Companies in the Medical Care Facilities

S.No.	Ticker	Company	Market Cap	P/E	P/S	Total Debt (Qtr)
1	HCA	HCA Healthcare, Inc.	87.94 Bn	11.25	1.15	48.02 Bn
2	CHE	Chemed Corp	18.08 Bn	51.68	7.12	0.09 Bn
3	THC	Tenet Healthcare Corp	16.59 Bn	9.74	0.77	13.21 Bn
4	DVA	Davita Inc.	15.37 Bn	14.02	1.10	10.63 Bn
5	EHC	Encompass Health Corp	10.07 Bn	654.20	1.66	2.57 Bn
6	ENSG	Ensign Group, Inc	9.52 Bn	27.18	1.81	0.14 Bn
7	UHS	Universal Health Services Inc	9.19 Bn	6.05	0.52	4.71 Bn
8	PACS	PACS Group, Inc.	6.96 Bn	28.55	1.28	0.05 Bn

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Research Tools

Developers

About

Investment Thesis

Segments Breakdown of Revenue (2025)

Segments Breakdown of Revenue (2025)

Peer Comparison

Create an account

Sign In

Reset Password